7 results match your criteria: "Salgrenska University Hospital[Affiliation]"
J Clin Oncol
June 2023
Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
J Sleep Res
June 2021
University of Parma, Parma, Italy.
Cancer Nurs
September 2017
Author Affiliations: Department of Oncology, Aalborg University Hospital, Denmark (Ms Pedersen and Drs Carus and Falkmer); Unit of Clincal Biostatistics and Bioinformatics, Aalborg University Hospital, and Department of Clinical Medicine, Aalborg University, Denmark (Ms Bendtsen); Clinical Nursing research Unit, Aalborg University Hospital, Denmark (Dr Groenkjaer); Institute of Public Health, Section of Nursing, Aarhus University, Denmark, and University College Diakonova, Oslo, Norway (Dr Delmar); and Clinical Nutrition Unit, Salgrenska University Hospital, Goethenburg, Sweden (Dr Boseaus).
Background: Antineoplastic adjuvant treatment for breast cancer can cause changes in women's weight and body composition and influence their general health and survival.
Objective: The aim of this study is to investigate the extent and patterns of change in weight and body composition after current standard adjuvant antineoplastic treatment for breast cancer.
Methods: Data on weight and body composition from 95 women with breast cancer Stage I to III were obtained during 18 months on a bioelectric impedance analyzer.
Acta Derm Venereol
November 2004
Department of Dermatology, Salgrenska University Hospital, Göteborg, Sweden.
Crit Care Med
November 2000
Department of Anesthesiology and Intensive Care, Salgrenska University Hospital, Göteborg, Sweden.
Objectives: To evaluate the association between changes in total splanchnic and mucosal perfusion, assessed either by gastric tonometry or jejunal laser Doppler flowmetry in postcardiac surgical patients.
Design: A prospective, observational study.
Settings: A general intensive care unit in a tertiary care center.
Int J Radiat Oncol Biol Phys
July 1996
Department of General Oncology, Salgrenska University Hospital, Gothenborg, Sweden.
Purpose: A controversy exists regarding whether it is safe to delay radiation therapy until the completion of chemotherapy following breast-conserving surgery for patients with node-positive breast cancer. Within the context of two concurrent randomized clinical trials we had the opportunity to evaluate outcomes for patients who received breast irradiation after completing different durations of chemotherapy.
Methods And Materials: From July 1986 to April 1993 the International Breast Cancer Study Group (IBCSG) Trial VI randomly assigned 1554 pre/perimenopausal node-positive breast cancer patients to receive cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) for either three consecutive courses on months 1-3, or six consecutive courses on months 1-6, both with or without reintroduction CMF.